Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design

An Author Correction to this article was published on 12 November 2018

This article has been updated


Inhibiting the interaction between amyloid-β (Aβ) and a neuronal cell surface receptor, LilrB2, has been suggested as a potential route for treating Alzheimer’s disease. Supporting this approach, Alzheimer’s-like symptoms are reduced in mouse models following genetic depletion of the LilrB2 homologue. In its pathogenic, oligomeric state, Aβ binds to LilrB2, triggering a pathway to synaptic loss. Here we identify the LilrB2 binding moieties of Aβ (16KLVFFA21) and identify its binding site on LilrB2 from a crystal structure of LilrB2 immunoglobulin domains D1D2 complexed to small molecules that mimic phenylalanine residues. In this structure, we observed two pockets that can accommodate the phenylalanine side chains of KLVFFA. These pockets were confirmed to be 16KLVFFA21 binding sites by mutagenesis. Rosetta docking revealed a plausible geometry for the Aβ–LilrB2 complex and assisted with the structure-guided selection of small molecule inhibitors. These molecules inhibit Aβ–LilrB2 interactions in vitro and on the cell surface and reduce Aβ cytotoxicity, which suggests these inhibitors are potential therapeutic leads against Alzheimer’s disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The 16KLVFFA21 segment of Aβ binds to LilrB2 D1D2.
Fig. 2: Crystal structure of LilrB2 D1D2 complexed with benzamidine.
Fig. 3: Mutagenesis studies and Rosetta docking validate the Aβ binding sites on LilrB2.
Fig. 4: Selected small molecules inhibit the Aβ–LilrB2 interaction in vitro.
Fig. 5: Selected inhibitors block LilrB2-induced cell attachment and inhibit toxicity of Aβ.
Fig. 6: Validation of ALI6 using primary neurons.

Data availability

The crystal structure reported here, LilrB2 D1D2 complexed with benzamidine, and the corresponding diffraction data have been deposited to the Protein Data Bank (PDB) with the accession code 6BCS. All other data are available upon reasonable request to the authors.

Change history

  • 12 November 2018

    In the version of this Article originally published online, the upper right panel of Fig. 5a was mistakenly a repeat of the lower right panel. This has now been corrected in all versions of the Article.


  1. Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992).

    Article  CAS  Google Scholar 

  2. Sheng, M., Sabatini, B. L. & Sudhof, T. C. Synapses and Alzheimer’ disease. Cold Spring Harb. Perspect. Biol. 4, a005777 (2012).

    Article  Google Scholar 

  3. Braak, H. & Braak, E. Alzheimer’s disease: striatal amyloid deposits and neurofibrillary changes. J. Neuropathol. Exp. Neurol. 49, 215–224 (1990).

    Article  CAS  Google Scholar 

  4. Nagy, Z. et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer’s disease. Neuroscience 69, 757–761 (1995).

    Article  CAS  Google Scholar 

  5. Seidler, P. M. et al. Structure-based inhibitors of tau aggregation. Nat. Chem. 10, 170–176 (2018).

    Article  CAS  Google Scholar 

  6. Tanzi, R. E. & Bertram, L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120, 545–555 (2005).

    Article  CAS  Google Scholar 

  7. Bettens, K., Sleegers, K. & Van Broeckhoven, C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum. Mol. Genet. 19, R4–R11 (2010).

    Article  CAS  Google Scholar 

  8. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448–6453 (1998).

    Article  CAS  Google Scholar 

  9. Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).

    Article  CAS  Google Scholar 

  10. Li, S. et al. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 31, 6627–6638 (2011).

    Article  CAS  Google Scholar 

  11. Hsiao, K. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99–102 (1996).

    Article  CAS  Google Scholar 

  12. Ashe, K. H. & Zahs, K. R. Probing the biology of Alzheimer’s disease in mice. Neuron 66, 631–645 (2010).

    Article  CAS  Google Scholar 

  13. Sorrentino, V. et al. Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity. Nature 552, 187–193 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhu, B. et al. ER-associated degradation regulates Alzheimer’s amyloid pathology and memory function by modulating ɣ-secretase activity. Nat. Commun. 8, 1472 (2017).

    Article  Google Scholar 

  15. Cheng, P. N., Liu, C., Zhao, M., Eisenberg, D. & Nowick, J. S. Amyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat. Chem. 4, 927–933 (2012).

    Article  CAS  Google Scholar 

  16. Man, B. Y.-W. et al. Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer’s disease. Chem. Sci. 2, 917 (2011).

    Article  CAS  Google Scholar 

  17. Ehrnhoefer, D. E. et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558–566 (2008).

    Article  CAS  Google Scholar 

  18. Dovey, H. F. et al. Functional ɣ-secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem. 76, 173–181 (2001).

    Article  CAS  Google Scholar 

  19. Evin, G. Future therapeutics in Alzheimer’s disease: development status of BACE inhibitors. BioDrugs 30, 173–194 (2016).

    Article  CAS  Google Scholar 

  20. Mitani, Y. et al. Differential effects between ɣ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32, 2037–2050 (2012).

    Article  CAS  Google Scholar 

  21. Castillo-Carranza, D. L., Guerrero-Munoz, M. J. & Kayed, R. Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or τ, which is the right target? Immunotargets Ther. 3, 19–28 (2014).

    PubMed  Google Scholar 

  22. Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).

    Article  CAS  Google Scholar 

  23. Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457, 1128–1132 (2009).

    Article  CAS  Google Scholar 

  24. Cisse, M. et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47–52 (2011).

    Article  CAS  Google Scholar 

  25. Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V. & Hooper, N. M. Amyloid-β receptors: the good, the bad, and the prion protein. J. Biol. Chem. 291, 3174–3183 (2016).

    Article  CAS  Google Scholar 

  26. Kim, T. et al. Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science 341, 1399–1404 (2013).

    Article  CAS  Google Scholar 

  27. Luhrs, T. et al. 3D structure of Alzheimer’s amyloid-β(1–42) fibrils. Proc. Natl Acad. Sci. USA 102, 17342–17347 (2005).

    Article  CAS  Google Scholar 

  28. Colletier, J. P. et al. Molecular basis for amyloid-β polymorphism. Proc. Natl Acad. Sci. USA 108, 16938–16943 (2011).

    Article  CAS  Google Scholar 

  29. Willcox, B. E. et al. Crystal structure of LIR-2 (ILT4) at 1.8 Å: differences from LIR-1 (ILT2) in regions implicated in the binding of the human cytomegalovirus class I MHC homolog UL18. BMC Struct. Biol. 2, 6 (2002).

    Article  Google Scholar 

  30. Raveh, B., London, N., Zimmerman, L. & Schueler-Furman, O. Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors. PLoS ONE 6, e18934 (2011).

    Article  CAS  Google Scholar 

  31. Stroud, J. C., Liu, C., Teng, P. K. & Eisenberg, D. Toxic fibrillar oligomers of amyloid-β have cross-β structure. Proc. Natl Acad. Sci. USA 109, 7717–7722 (2012).

    Article  CAS  Google Scholar 

  32. Kuhlman, B. & Baker, D. Native protein sequences are close to optimal for their structures. Proc. Natl Acad. Sci. USA 97, 10383–10388 (2000).

    Article  CAS  Google Scholar 

  33. Lawrence, M. C. & Colman, P. M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946–950 (1993).

    Article  CAS  Google Scholar 

  34. Jiang, L. et al. Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid β. eLife 2, e00857 (2013).

    Article  Google Scholar 

  35. Huang, H. C., Chang, P., Dai, X. L. & Jiang, Z. F. Protective effects of curcumin on amyloid-β-induced neuronal oxidative damage. Neurochem. Res. 37, 1584–1597 (2012).

    Article  CAS  Google Scholar 

  36. He, Y. et al. Prolonged exposure of cortical neurons to oligomeric amyloid-β impairs NMDA receptor function via NADPH oxidase-mediated ROS production: protective effect of green tea (−)-epigallocatechin-3-gallate. ASN Neuro. 3, e00050 (2011).

    PubMed  PubMed Central  Google Scholar 

  37. Syken, J., Grandpre, T., Kanold, P. O. & Shatz, C. J. PirB restricts ocular-dominance plasticity in visual cortex. Science 313, 1795–1800 (2006).

    Article  CAS  Google Scholar 

  38. Gremer, L. et al. Fibril structure of amyloid-β(1–42) by cryo-electron microscopy. Science 358, 116–119 (2017).

    Article  CAS  Google Scholar 

  39. Liu, C. et al. Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates. Proc. Natl Acad. Sci. USA 109, 20913–20918 (2012).

    Article  CAS  Google Scholar 

  40. Laganowsky, A. et al. Atomic view of a toxic amyloid small oligomer. Science 335, 1228–1231 (2012).

    Article  CAS  Google Scholar 

  41. Nalivaeva, N. N., Belyaev, N. D., Kerridge, C. & Turner, A. J. Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer’s disease. Front. Aging Neurosci. 6, 235 (2014).

    Article  Google Scholar 

  42. Crespi, G. A., Hermans, S. J., Parker, M. W. & Miles, L. A. Molecular basis for mid-region amyloid-β capture by leading Alzheimer’s disease immunotherapies. Sci. Rep. 5, 9649 (2015).

    Article  CAS  Google Scholar 

  43. Abbott, A. & Dolgin, E. Failed Alzheimer’s trial does not kill leading theory of disease. Nature 540, 15–16 (2016).

    Article  CAS  Google Scholar 

  44. Wang, S. et al. D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358, 381–386 (2017).

    Article  CAS  Google Scholar 

Download references


The authors thank C. Shatz for providing the LilrB2 plasmid. This work is based on research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P41 GM103403). The Pilatus 6M detector on the 24-ID-C beamline is funded by a NIH-ORIP HEI grant (S10 RR029205). This research used resources from the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. L.J. is supported by UCLA departmental recruitment funds. The authors also acknowledge NIH AG 054022 and DOE DE-FC02-02ER63421 for support.

Author information

Authors and Affiliations



Q.C., D.S.E. and L.J. conceived and designed the experiments. Q.C., W.S.S., H.C., C.K.V., B.D. and B.L. performed the experiments. W.S.S., B.D., K.A.M. and L.J. performed computational docking and structure-guided selection of small molecules. H.C. and J.F. performed and analysed NMR experiments. B.L. and L.J. performed and analysed circular dichroism experiments. C.K.V. and D.L.B. cultured primary neurons. Q.C. and M.R.S. solved the structure of the LilrB2 and benzamidine complex. All authors discussed the results and commented on the manuscript. Q.C., D.S.E. and L.J. analysed the data and co-wrote the paper.

Corresponding authors

Correspondence to David S. Eisenberg or Lin Jiang.

Ethics declarations

Competing interests

D.S.E. is an advisor and equity shareholder in ADDRx.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Methods and materials, Supplementary Figures 1–7, and Supplementary Table 1–4

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cao, Q., Shin, W.S., Chan, H. et al. Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design. Nature Chem 10, 1213–1221 (2018).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research